Half Year 2026 argenx SE Earnings Call Transcript
Key Points
- argenx SE (ARGNF) reported its 18th consecutive quarter of growth, highlighting strong momentum and consistent performance.
- VYVGART has been approved for seronegative generalized Myasthenia Gravis (gMG), making it the first treatment approved across all serotypes of gMG.
- The company achieved a 60% year-over-year growth in product net sales, with significant contributions from the US, Japan, and other regions.
- argenx SE (ARGNF) has a robust pipeline with two registrational readouts expected before the end of the year, supporting its goal of achieving 10 labeled indications.
- The company maintains a strong financial position with a cash balance of $5.2 billion, allowing for reinvestment in scientific innovation and potential business development opportunities.
- Total operating expenses increased by $129 million compared to the first quarter, reflecting higher R&D and SG&A investments.
- The company faces competition in the MG market, with new launches and upcoming launches from competitors potentially impacting market share.
- There are concerns about the efficacy and safety of FcRn therapies, with some competitors suggesting potential dropouts due to safety observations.
- The development of Empasiprubart in the transplant setting did not support DGF as an indication, indicating challenges in expanding its use.
- The company faces challenges in changing entrenched habits among physicians and payers to adopt VYVGART as a first-line treatment for CIDP.
Good morning. My name is Laila, and I will be your conference operator today. I would like to welcome everyone to the call. (Operator Instructions) Thank you.
I'd like to introduce Beth DelGiacco, Vice President of Corporate Affairs. You may now begin your call.
Thank you. A press release was issued earlier today with our second quarter 2026 financial results and business update. This can be found on our website along with the presentation for today's webcast.
Before we begin, on slide 2, I'd like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory timelines, the potential success of our product candidates, financial projections, and upcoming milestones.
Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to update statements regarding the future or to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
